4:31 PM
 | 
May 17, 2017
 |  BC Extra  |  Company News

Management tracks

Protein therapeutics company Molecular Partners AG (SIX:MOLN) named Patrick Amstutz CEO. Amstutz had been acting CEO since the November 2016 resignation of Christian Zahnd.

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) said CEO Gur Roshwalb will be placed on administrative leave pending investigation of an inaccurate report from Edison Investment Research Ltd. Executive Chairman Ray Prudo is leading the company in Roshwalb's absence.

Cannabinoid company GW Pharmaceuticals plc (NASDAQ:GWPH) named...

Read the full 352 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >